Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
published in: The Lancet
date of publication: 2017-10-06
language: English
main subject: phase III clinical trial, placebo, chemotherapy
Cites articles 30
- 2015-09-25
Date
Title
Article - wd:Q47745009